Alaniz Cesar, Mohammad Rima A, Welage Lynda S
Department of Pharmacy Services, College of Pharmacy, University of Michigan Hospitals and Health Centers, Ann Arbor, Michigan 48109, USA.
Pharmacotherapy. 2009 Mar;29(3):248-54. doi: 10.1592/phco.29.3.248.
To assess the effect of a prolonged continuous infusion of pantoprazole on patient outcomes when the drug was combined with standard octreotide therapy in patients with variceal hemorrhage.
Retrospective cohort study.
Large academic hospital. Patients. One hundred thirty adults who received treatment for a documented variceal hemorrhage; 53 patients received standard octreotide therapy plus a prolonged continuous infusion of pantoprazole (continuous-infusion group) and 77 patients received either octreotide alone, octreotide with a short-term (<24 hrs) infusion of pantoprazole, or octreotide with intermittent acid suppression (control group).
The primary outcome measure was the number of units of packed red blood cells transfused during hospitalization. Baseline characteristics between the treatment groups were similar. The duration of therapy for variceal hemorrhage was significantly longer in the continuous-infusion group than in the control group. Transfusion requirements for packed red blood cells (mean+/-SD 6.4+/-6.5 vs 5.8+/-6.6 units, p=0.66) and platelets (8.8+/-15.1 vs 5.1+/-11.9 units, p=0.13) were similar for the continuous-infusion group versus the control group. The continuous-infusion group, however, received significantly more units of fresh-frozen plasma than the control group (6.1+/-10.6 vs 2.9+/-6.2 units, p=0.05). There was no significant difference in mortality rate between groups.
Prolonged continuous infusions of pantoprazole with octreotide seemed to offer no additional benefit compared with octreotide plus short-term infusions of pantoprazole or intermittent acid suppression in the management of acute variceal hemorrhage. Prospective studies should be conducted to evaluate the role of continuously infused proton pump inhibitors in this setting before their use can be advocated.
评估在静脉曲张出血患者中,泮托拉唑持续长时间输注联合标准奥曲肽治疗对患者预后的影响。
回顾性队列研究。
大型学术医院。患者:130名确诊为静脉曲张出血并接受治疗的成年人;53名患者接受标准奥曲肽治疗加泮托拉唑持续长时间输注(持续输注组),77名患者接受单独奥曲肽治疗、奥曲肽加短期(<24小时)泮托拉唑输注或奥曲肽加间歇性抑酸治疗(对照组)。
主要结局指标是住院期间输注的红细胞悬液单位数。治疗组间的基线特征相似。持续输注组静脉曲张出血的治疗持续时间显著长于对照组。持续输注组与对照组的红细胞悬液(平均±标准差6.4±6.5单位对5.8±6.6单位,p=0.66)和血小板(8.8±15.1单位对5.1±11.9单位,p=0.13)输注需求相似。然而,持续输注组接受的新鲜冰冻血浆单位数显著多于对照组(6.1±10.6单位对2.9±6.2单位,p=0.05)。两组间死亡率无显著差异。
在急性静脉曲张出血的治疗中,与奥曲肽加短期泮托拉唑输注或间歇性抑酸相比,泮托拉唑与奥曲肽持续长时间输注似乎没有额外益处。在提倡使用之前,应进行前瞻性研究以评估持续输注质子泵抑制剂在此情况下的作用。